The FDA has approved the drug ANKTIVA to be used with the existing immunotherapy drug BCG for nonmuscle-invasive bladder cancer. This new treatment reduces the need for bladder removal surgery and has shown promising results in clinical trials. Patients who received ANKTIVA plus BCG had high rates of tumor disappearance and survival, with minimal side effects. ANKTIVA is not effective on its own but works synergistically with BCG to boost the immune system’s ability to fight cancer cells. This treatment option offers hope for patients with nonmuscle-invasive bladder cancer who have not responded to traditional therapies.
Source link
New FDA approved treatment for bladder cancer
